Here are the DEF 14A proxy statements from Bolt Biotherapeutics, Inc. (BOLT) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow BOLT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BOLT filings page.
Bolt Biotherapeutics, Inc. is holding its 2026 annual stockholder meeting virtually on June 10, 2026 at 11:00 a.m. Pacific Time via www.proxydocs.com/BOLT. Stockholders of record as of April 22, 2026, when 1,921,567 common shares were outstanding, may vote.
Stockholders will vote on electing two Class II directors, William P. Quinn and Jakob Dupont, M.D., to serve until the 2029 annual meeting, and on ratifying PricewaterhouseCoopers LLP as independent registered public accounting firm for the year ending December 31, 2026. The Board recommends voting FOR both proposals.